Camilla Zimmermann MD PhD

Research team at @pmcancercentre @UofT_DoM focused on palliative care. Key interest is enabling access to palliative care for all.

[Princess Margaret Cancer Centre Research @PMResearch_UHN]

Rethinking Novel Therapy Use in End-of-Life Cancer Care

Research from @UHN’s @ZimmTeamLab reports a rising use of systemic anticancer therapies at the end of life—primarily driven by cancer immunotherapy. This trend raises important concerns.

@JCO_ASCO: https://t.co/TMFs9EIZRV

[Camilla Zimmermann MD PhD @ZimmTeamLab]

@EAEisenhauer Thank you!

[Camilla Zimmermann MD PhD @ZimmTeamLab]

Urgent need for updated guidelines on Systemic Anticancer Therapy use at #EndofLife: Our study of 68,000+ patients found use of novel SACT at EOL, including immunotherapy, was associated with indicators of poor-quality #EndofLifeCare. https://t.co/HJbzZK3g9a @JCO_ASCO @thePMCF

[Department of Supportive Care @UHN_Supportive]

#NewPublication from @ZimmTeamLab @GRodinResearch @HannonBreffni @JPSMjournal: "Impact of caregiver and patient age on efficacy of caregiver interventions in advanced cancer: a meta-regression."

#SupportiveCare

https://t.co/q1EIJynD9G

[Samantha Winemaker she/her @SammyWinemaker]

I will never get tired of listening to @HMChochinov !!!

His address to the medical class of 2028.

Should be a mandatory video for all #Doctors to watch to remind them that our #Patients are people.

Thank you Harvey!🎤

https://t.co/vpdGfmGLmu

#MedTwitter #MedEd #Palliative

[Journal of Clinical Oncology @JCO_ASCO]

Corticosteroids for Immune-Related Adverse Events and
Checkpoint Inhibitor Efficacy: Analysis of Six #ClinicalTrials. @UMCUtrecht @annemariamay

https://t.co/pyJvN196Iv

[Fred Ashbury PhD FMASCC @viecure_ashbury]

Please mark this date in your calendar. Looking forward to MASCC 2025!

[Camilla Zimmermann MD PhD @ZimmTeamLab]

New editorial discusses recent RCT published in @JCO_ASCO: Oral cannabis (THC:CBD) extract promising for patients with refractory chemotherapy-induced nausea and vomiting. Further trials needed comparing with other antiemetics, particularly olanzapine. https://t.co/6F6tIsboOt

[Camilla Zimmermann MD PhD @ZimmTeamLab]

Routine symptom screening tools may represent an opportunity for oncology teams to identify and treat burdensome symptoms and to stratify patients for triaged referral to specialist services.
Read our new editorial in @JCOOP_ASCO: https://t.co/vaQKxYxK0g

[Billy Rosa, PhD, MBE, APRN @BillyRosaPhD]

💻Our next @PalliativeMed_j Top Ten paper on what #PalliativeCare clinicians should know about interpreting a clinical trial➡️excellent guidance to informed evidence-based practice📚Stay tuned for partner article on designing a clinical trial🔗:https://t.co/p3F0ZYU99m #hapc #hpm

[The Lancet Oncology @TheLancetOncol]

Online First:

Celiac plexus #radiosurgery for #pain management in advanced #cancer: a multicentre, single-arm, phase 2 trial

https://t.co/aRvyRwSf6t

[Department of Supportive Care @UHN_Supportive]

Big weekend for
@thePMCF
- it's the 2024 Ride to Conquer Cancer! It was an honour and a privilege to send off our very own Team Supportive Care this morning! Our Ride team raised a whopping $50,000! Way to go!

[Department of Supportive Care @UHN_Supportive]

Just 1 week away! There's still time to register for the inaugural Supportive Care Update Conference at: https://t.co/MXPfriEJIQ

[CMAJ @CMAJ]

People with opioid use disorder are less likely to receive palliative care in communities during the 90 days before death.
➡️ https://t.co/ipPrBisNsv
@JelauPC @marym_scott @Tara_Gomes @ZimmTeamLab @sarina_isenberg @virtualhospice @PCPCRCollab @CIHR_IRSC @bruyerecare

[Common Sense Oncology @csoncol]

Common Sense Oncology leadership team is having its first annual meeting next week in Montreal. Our opening plenary session will be open to all CSO members. Join us by zoom for the LIVE plenary session with these leaders in our field.
Register for zoom link here- https://t.co/z8sy4Gfu8L

[University Health Network @UHN]

Researchers at UHN's @pmcancercentre found that the #COVID19 pandemic led to increased disparities in end-of-life care for patients with cancer.

Learn how @ZimmTeamLab’s study can lead to more equitable palliative care ⬇
https://t.co/bh7pMUOp0b

[Department of Supportive Care @UHN_Supportive]

#RecentPublication "Palliative Care as a Component of High-Value and Cost-Saving Care During Hospitalization for Metastatic Cancer" @ZimmTeamLab https://t.co/tbllTMn67r

[C. Jillian Tsai, MD, PhD @CJTsaiMDPhD]

🚨In this original report, we found that increased utilization of palliative care during hospitalization for patients with metastatic cancer, including early consultations for younger patients and irrespective of receiving invasive medical procedures, has the capacity to increase high-value care and alleviate the economic burden on patients and the health care system.

Palliative Care as a Component of High-Value and Cost-Saving Care During Hospitalization for Metastatic Cancer | JCO Oncology Practice https://t.co/JUEewmhrMs

@EileenRakovitch @ZimmTeamLab @MichaelYanMD @DrJohndeAlmeida @YaoCMKL @ErinGillespieMD @fumikochino @SaraMheid @UofTDRO @RadMedPM @UHN @pmcancercentre @DKirschMDPhD

[Princess Margaret Cancer Centre Research @PMResearch_UHN]

Disparities in end-of-life care 🕰️

The pandemic caused more cancer patients to die at home and less delivery of palliative care. The low socioeconomic group was the hardest hit, as their increase in home deaths was not accompanied by palliative care.

>> https://t.co/zFuIOHfLWF

[CMAJ @CMAJ]

This study highlights the wide-ranging views held by health leaders regarding the optimal relationship between MAiD and palliative and end-of-life care in Canada.
➡️ https://t.co/alwQvQ38Gg
@gkshapiro @eryn_tong @ZimmTeamLab @allin_sara @GibsonJennifer @madli8 @gary_rodin